In Reply Starting January 1, 2020, as a result of the 2018 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, Medicare Part B has provided a bundled payment for opioid addiction treatment in an opioid treatment program.1
This advance, however, does not address the concerns of Gifford and colleagues about the inability of long-term care facilities to obtain methadone from community pharmacies to treat opioid use disorder. As discussed in our Viewpoint,2 current Drug Enforcement Administration regulations only allow pharmacies to supply these facilities with methadone for short-term withdrawal management, known as detoxification, of patients with opioid use disorder. This clinical use is associated with poor outcomes.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Pytell JD, Sharfstein JM, Olsen Y. Additional Barriers to Methadone Use in Hospitals and Skilled Nursing Facilities—Reply. JAMA Intern Med. 2020;180(4):615. doi:10.1001/jamainternmed.2020.0117
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: